JAKARTA (TheInsiderStories) – Coronavac vaccine has officially get Emergency Use Authorization from the Indonesian Food and Drug Administration although the level of efficacy only 65.3 percent, over the World Health Organization standard around 50 percent. The COVID-19 vaccine produced by Chinese drug-maker, Sinovac.
The head, Penny Kusumastuti Lukito, said in a virtual press conference today, the vaccine is safe and the side effects are mild and moderate based on the monitoring and analysis results from clinical trials conducted in Indonesia and the results of clinical trials in Brazil and Turkey.
The Coronavac vaccine has demonstrated the ability to form antibodies in the human body and also the ability of antibodies to kill or neutralize viruses seen starting from clinical trials phase 1 and 2 in China, with a monitoring period up to six months. In the phase 3 clinical trial in Bandung, immunogenicity data showed good results, she noted.
Lukito explained, 14 days after injection with seropositive results the ability of the vaccine to form antibodies around 99.74 percent. After three months injection, the seropositive result was 99.23 percent. In comparison, the efficacy of the vaccine in Turkey was 91.25 percent and in Brazil it was 78 percent.
“The reduction in the number of COVID-19 infections with the vaccine will be very meaningful in our efforts to get out from the pandemic crisis,” she said.
At the same day, Indonesian government also stated that it would get hundreds of millions of doses of the COVID-19 vaccine for free from the Global Alliance for Vaccine and Immunization (GAVI) and COVAX. Health minister, Budi Gunadi Sadikin, the country could get 108 million doses of vaccines for free.
He asserter, that the free vaccines from GAVI and COVAX consisted of Pfizer, AstraZeneca, and Moderna vaccines. The three vaccines will certainly get a license to use before being shipped to Indonesia. The plan is that on Jan. 13, the COVID-19 vaccination program will begin and President Joko Widodo will be the first person to be injected with the Sinovac’ vaccine.
Written by Editorial Staff, Email: firstname.lastname@example.org